Behaviour of von willebrand factor antigen in follow-up of polymyalgia rheumatica/giant cell arteritis

M. L. Ciompi, G. Marotta, L. Puccetti, E. Remorini, G. Petrini, M. Zuccotti, M. Vispi, U. Baicchi, P. Iacconi

Research output: Contribution to journalArticle

Abstract

The von Willebrand Factor Antigen (vWF: Ag) is a high molecular weight glycoprotein synthesized by endothelial cells and megakaryocytes. It is present inside the endothelium cells in Welbel-Palade bodies (1) and is also present in the alpha granules of platelets (2). Elevated levels of vWF: Ag have been reported in several diseases characterized by vessel injury, such as scleroderma (3), glomerulonephritis (4), diabetes mellitus (5), Behcet's syndrome (6), Systemic Lupus Erythematosus, Rheumatoid Arthritis and vasculitis in general (7). Increased vWF: Ag plasma levels have also been described in patients with Giant Cell Arteritis (GCA) and/or Polymyalgia Rheumatic (PMR) (8, 9). In both these diseases an apparent or clinically hidden vasculitis is or may be present and vWF: Ag is reported to be most helpful in discriminating between PMR and GCA, since its levels seem to be higher in patients affected by GCA (8, 9).

Original languageEnglish
Pages (from-to)491-495
Number of pages5
JournalScandinavian Journal of Rheumatology
Volume17
Issue number6
DOIs
Publication statusPublished - 1988

Fingerprint

Polymyalgia Rheumatica
Giant Cell Arteritis
von Willebrand Factor
Rheumatoid Vasculitis
Megakaryocytes
Behcet Syndrome
Glomerulonephritis
Vasculitis
Systemic Lupus Erythematosus
Endothelium
Rheumatoid Arthritis
Glycoproteins
Diabetes Mellitus
Blood Platelets
Endothelial Cells
Molecular Weight
Von Willebrand antigen
Wounds and Injuries

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy

Cite this

Behaviour of von willebrand factor antigen in follow-up of polymyalgia rheumatica/giant cell arteritis. / Ciompi, M. L.; Marotta, G.; Puccetti, L.; Remorini, E.; Petrini, G.; Zuccotti, M.; Vispi, M.; Baicchi, U.; Iacconi, P.

In: Scandinavian Journal of Rheumatology, Vol. 17, No. 6, 1988, p. 491-495.

Research output: Contribution to journalArticle

Ciompi, ML, Marotta, G, Puccetti, L, Remorini, E, Petrini, G, Zuccotti, M, Vispi, M, Baicchi, U & Iacconi, P 1988, 'Behaviour of von willebrand factor antigen in follow-up of polymyalgia rheumatica/giant cell arteritis', Scandinavian Journal of Rheumatology, vol. 17, no. 6, pp. 491-495. https://doi.org/10.3109/03009748809098813
Ciompi, M. L. ; Marotta, G. ; Puccetti, L. ; Remorini, E. ; Petrini, G. ; Zuccotti, M. ; Vispi, M. ; Baicchi, U. ; Iacconi, P. / Behaviour of von willebrand factor antigen in follow-up of polymyalgia rheumatica/giant cell arteritis. In: Scandinavian Journal of Rheumatology. 1988 ; Vol. 17, No. 6. pp. 491-495.
@article{3e8e9092776a4afdbf3c7ac678976d3c,
title = "Behaviour of von willebrand factor antigen in follow-up of polymyalgia rheumatica/giant cell arteritis",
abstract = "The von Willebrand Factor Antigen (vWF: Ag) is a high molecular weight glycoprotein synthesized by endothelial cells and megakaryocytes. It is present inside the endothelium cells in Welbel-Palade bodies (1) and is also present in the alpha granules of platelets (2). Elevated levels of vWF: Ag have been reported in several diseases characterized by vessel injury, such as scleroderma (3), glomerulonephritis (4), diabetes mellitus (5), Behcet's syndrome (6), Systemic Lupus Erythematosus, Rheumatoid Arthritis and vasculitis in general (7). Increased vWF: Ag plasma levels have also been described in patients with Giant Cell Arteritis (GCA) and/or Polymyalgia Rheumatic (PMR) (8, 9). In both these diseases an apparent or clinically hidden vasculitis is or may be present and vWF: Ag is reported to be most helpful in discriminating between PMR and GCA, since its levels seem to be higher in patients affected by GCA (8, 9).",
author = "Ciompi, {M. L.} and G. Marotta and L. Puccetti and E. Remorini and G. Petrini and M. Zuccotti and M. Vispi and U. Baicchi and P. Iacconi",
year = "1988",
doi = "10.3109/03009748809098813",
language = "English",
volume = "17",
pages = "491--495",
journal = "Scandinavian Journal of Rheumatology",
issn = "0300-9742",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Behaviour of von willebrand factor antigen in follow-up of polymyalgia rheumatica/giant cell arteritis

AU - Ciompi, M. L.

AU - Marotta, G.

AU - Puccetti, L.

AU - Remorini, E.

AU - Petrini, G.

AU - Zuccotti, M.

AU - Vispi, M.

AU - Baicchi, U.

AU - Iacconi, P.

PY - 1988

Y1 - 1988

N2 - The von Willebrand Factor Antigen (vWF: Ag) is a high molecular weight glycoprotein synthesized by endothelial cells and megakaryocytes. It is present inside the endothelium cells in Welbel-Palade bodies (1) and is also present in the alpha granules of platelets (2). Elevated levels of vWF: Ag have been reported in several diseases characterized by vessel injury, such as scleroderma (3), glomerulonephritis (4), diabetes mellitus (5), Behcet's syndrome (6), Systemic Lupus Erythematosus, Rheumatoid Arthritis and vasculitis in general (7). Increased vWF: Ag plasma levels have also been described in patients with Giant Cell Arteritis (GCA) and/or Polymyalgia Rheumatic (PMR) (8, 9). In both these diseases an apparent or clinically hidden vasculitis is or may be present and vWF: Ag is reported to be most helpful in discriminating between PMR and GCA, since its levels seem to be higher in patients affected by GCA (8, 9).

AB - The von Willebrand Factor Antigen (vWF: Ag) is a high molecular weight glycoprotein synthesized by endothelial cells and megakaryocytes. It is present inside the endothelium cells in Welbel-Palade bodies (1) and is also present in the alpha granules of platelets (2). Elevated levels of vWF: Ag have been reported in several diseases characterized by vessel injury, such as scleroderma (3), glomerulonephritis (4), diabetes mellitus (5), Behcet's syndrome (6), Systemic Lupus Erythematosus, Rheumatoid Arthritis and vasculitis in general (7). Increased vWF: Ag plasma levels have also been described in patients with Giant Cell Arteritis (GCA) and/or Polymyalgia Rheumatic (PMR) (8, 9). In both these diseases an apparent or clinically hidden vasculitis is or may be present and vWF: Ag is reported to be most helpful in discriminating between PMR and GCA, since its levels seem to be higher in patients affected by GCA (8, 9).

UR - http://www.scopus.com/inward/record.url?scp=0024235591&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024235591&partnerID=8YFLogxK

U2 - 10.3109/03009748809098813

DO - 10.3109/03009748809098813

M3 - Article

C2 - 3266032

AN - SCOPUS:0024235591

VL - 17

SP - 491

EP - 495

JO - Scandinavian Journal of Rheumatology

JF - Scandinavian Journal of Rheumatology

SN - 0300-9742

IS - 6

ER -